ArticleNature medicine2021

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.

Jay Y Spiegel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.